Citation APA
Rossignol, P., Zannad, F., Massy, Z. A., Azizi, M., Chorfa, F., Coadic, J., Ferreira, J. P., Saraiva, F., Mottier, D., Guillemin, F., Ngueyon Sime, W., Bouali, S., Rossignol, B., Nortier, J., Simon, I., Robino, C., Davin, M., Bataille, P., Chantrel, F., Castin, N., Esnault, V., Kazes, I., Hannedouche, T., Kamar, N., Achard, J. M., Fenerol, C., Achard-Hottelart, C., Dimitrov, Y., Girerd, N., Maucourt-Boulch, D., & Frimat, L. (2025). Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet, 406(10504), 705-718. doi:10.1093/ced/llae373
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/396343